NCT05877859 is a clinical trial in Breast Cancer Triple Negative, sponsored by Emory University.

Who is sponsoring NCT05877859?

NCT05877859 is sponsored by Emory University.

What condition does NCT05877859 study?

NCT05877859 studies Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive.

Is NCT05877859 still recruiting?

NCT05877859 is currently recruiting now. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT05877859

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Recruiting now Last updated 14 May 2025

What this trial tests

trial in Breast Cancer Triple Negative in 10 participants. Currently enrolling.

Timeline

30 May 2023

Primary endpoint
10 April 2026

10 April 2027

Quick facts

Lead sponsor	Emory University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	10
Start date	30 May 2023
Primary completion	10 April 2026
Estimated completion	10 April 2027
Sites	1 location across United States

Conditions studied

Breast Cancer Triple Negative — all drugs for Breast Cancer Triple Negative →
Breast Cancer Stage II — all drugs for Breast Cancer Stage II →
Breast Cancer Stage III — all drugs for Breast Cancer Stage III →
Breast Cancer Invasive — all drugs for Breast Cancer Invasive →

Sponsor

Emory University

Who can join

18 and older, female only, with Breast Cancer Triple Negative or Breast Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Triple Negative

Currently open trials in the same condition.

NCT06532812 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer · Phase 1, PHASE2 · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05877859 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05877859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing